173 related articles for article (PubMed ID: 30340752)
21. New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings.
El Bairi K; Madariaga A; Trapani D; Al Jarroudi O; Afqir S
Int J Gynecol Cancer; 2024 May; 34(5):760-772. PubMed ID: 38101815
[TBL] [Abstract][Full Text] [Related]
22. [Cancer immunotherapy: Rational and recent breakthroughs].
Granier C; Karaki S; Roussel H; Badoual C; Tran T; Anson M; Fabre E; Oudard S; Tartour E
Rev Med Interne; 2016 Oct; 37(10):694-700. PubMed ID: 27370898
[TBL] [Abstract][Full Text] [Related]
23. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
24. Future directions for pediatric and young adult bone sarcoma.
Finney J; Kent PM; Batus M
Curr Probl Cancer; 2013; 37(4):225-35. PubMed ID: 24238588
[No Abstract] [Full Text] [Related]
25. Perspectives from the American Society of Clinical Oncology 2014 Conference: breast cancer highlights.
Crozier JA; Perez EA
Future Oncol; 2014 Oct; 10(12):1897-9. PubMed ID: 25386807
[No Abstract] [Full Text] [Related]
26. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
27. Awaiting a new era of cancer immunotherapy.
Hong CW; Zeng Q
Cancer Res; 2012 Aug; 72(15):3715-9. PubMed ID: 22815525
[TBL] [Abstract][Full Text] [Related]
28. Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Dimou AT; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):324-7. PubMed ID: 20601803
[TBL] [Abstract][Full Text] [Related]
29. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
30. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
31. Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting.
Lukas RV; Amidei C
Tumori; 2014; 100(3):358-62. PubMed ID: 25076251
[TBL] [Abstract][Full Text] [Related]
32. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".
Capitini CM; Gottschalk S; Brenner M; Cooper LJ; Handgretinger R; Mackall CL
Pediatr Hematol Oncol; 2011 Sep; 28(6):459-60. PubMed ID: 21854215
[TBL] [Abstract][Full Text] [Related]
33. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
34. Are peptide vaccines viable in combination with other cancer immunotherapies?
Ohtake J; Sasada T
Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
[No Abstract] [Full Text] [Related]
35. An Update on the Use of Immunotherapy in the Treatment of Lymphoma.
Marron TU; Kalac M; Brody J
Curr Hematol Malig Rep; 2017 Aug; 12(4):282-289. PubMed ID: 28735365
[TBL] [Abstract][Full Text] [Related]
36. 2015 ASCO Annual Meeting.
Coburn C
Lancet Oncol; 2015 Jul; 16(7):755-6. PubMed ID: 26062778
[No Abstract] [Full Text] [Related]
37. [Immunotherapies and targeted therapies in medical oncology].
Rousseau B; Champiat S; Loirat D; Arrondeau J; Lemoine N; Soria JC
Bull Cancer; 2014 Jan; 101(1):31-9. PubMed ID: 24333964
[TBL] [Abstract][Full Text] [Related]
38. Neuro-oncology: a selected review of ASCO 2011 abstracts.
Chamberlain MC
Expert Rev Neurother; 2011 Oct; 11(10):1371-7. PubMed ID: 21955193
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merika E; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
[TBL] [Abstract][Full Text] [Related]
40. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Patel JD; Krilov L; Adams S; Aghajanian C; Basch E; Brose MS; Carroll WL; de Lima M; Gilbert MR; Kris MG; Marshall JL; Masters GA; O'Day SJ; Polite B; Schwartz GK; Sharma S; Thompson I; Vogelzang NJ; Roth BJ
J Clin Oncol; 2014 Jan; 32(2):129-60. PubMed ID: 24327669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
